| DB ID | MyCo_3021 |
| Title | The current management landscape: aspergillosis |
| Year | 2016 |
| PMID | 27880666 |
| Fungal Diseases involved | Invasive aspergillosis |
| Associated Medical Condition | None |
| Genus | Aspergillus |
| Species | spp. |
| Organism | Aspergillus spp. |
| Ethical Statement | None |
| Site of Infection | None |
| Opportunistic invasive | Invasive |
| Sample type | Body fluid |
| Sample source | Blood |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Sweden |
| Cohort | None |
| Cohort No. | None |
| Age Group | None |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Invasive aspergillosis (IA), usually affecting the respiratory tract, occurs almost exclusively in patients with varying degrees of immunodeficiency, and produces a wide range of clinical manifes- tations. The nature and extent of the compromised immunity, as well as the prophylactic use of antifungals and accommodation in protective environments, predict the risk. Patients at high risk include allogeneic stem cell transplant recipients, those being treated for acute myeloid leukaemia, myelodysplastic syndromes or aplastic anaemia, and subgroups of solid organ transplant recipients. |
| Technique | ELISA |
| Analysis Method | FDA approved Fungitell assay |
| ELISA kits | None |
| Assay Data | None |
| Validation Techniques used | ELISA Based, Aspergillus PCR, FDA approved Fungitell assay |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
